Antivirals Flashcards
fusion inhibitors for treatment of retrovirus (HIV)
enfuvirtide, maraviroc
nucleoside reverse transcriptase inhibitors for treatment of retrovirus
zidovudine, didanosine, lamivudine, stavudine, abacavir
non-nucleoside reverse transcriptase inhibitors for treatment of retrovirus
nevirapine, delavirdine, efavirenz
integrase inhibitor for treatment of retrovirus
raltegravir
nucleotide inhibitor for treatment of retrovirus
tenofovir
protease inhibitors for treatment of retrovirus
atazanavir, saquinavir, ritonavir, lopinavir, indinavir, nelfinavir
treatments for herpes simplex and varicella zoster
acyclovir, valacyclovir, famciclovir, penciclovir
treatments for cytomegalovirus
ganciclovir, valganciclovir, cidofovir, foscarnet
treatments for hep B and C
lamivudine, adefovir, interferon alpha, ribavirin, boceprevir, telaprevir, tenofovir
uncoating inhibitors for treatment of influenza
amantadine, rimantadine
viral release inhibitors for treatment of influenza
zanamivir, oseltamivir
HAART
highly active antiretroviral therapy
36 amino acid synthetic peptide, increases effectiveness of HAART in combination chemotherapy, binds to gp41 of viral envelope, prevents conformational change and impedes the fusion of the viral and host cell membranes, no cross resistance with other HIV agents, potential for resistance developing when given at suboptimal doses
enfuvirtide
a 2nd line treatment; SC; high protein binding; metabolized by proteolytic hydrolysis; injection site reactions; increased risk of bacterial pneumonia
enfuvirtide
chemokine receptor 5 antagonist; binds to CCR5 co-receptor; prevents virus from entering the host cell; oral; substrate for both CYP3A4 and P-glycoprotein; both feces and urine
maraviroc
treatment of CCR5-tropic HIV-1; in combination for patients failing other antiretrovirals, coreceptor tropism assay should be performed when a CCR5 antagonist is being considered
maraviroc
adverse effects: cough, pyrexia, rash, musculoskeletal symptoms, abdominal pain and postural dizziness, bladder irritation; possible liver and cardiac problems; interacts with CYP3A inducers and inhibitors
maraviroc
AZT (zidovudine) and 3TC (lamivudine)
combivir
AZT (zidovudine) and 3TC (lamivudine) and abacavir
trizivir
mech of action of which retroviral group: competitive inhibition of viral reverse transcriptase
NRTIs
NRTIs: analogs of pyrimidine nucleoside (T); phosphorylated to active triphosphate forms; competes w/ deoxythymidine triphosphate for incorporation into DNA
zidovudine and stavudine
NRTIs: analogs of pyrimidine nucleoside (C); compete with deoxycytidine triphosphate for incorporation into viral DNA
lamivudine and emtricitabine
NRTI: analog of purine nucleoside (A, G); active 2’,3’-dideoxyadenosine 5’-triphosphate (ddATP) competes with cellular deoxyadenosine triphosphate for incorporation into viral DNA
didanosine
NRTI: analog of purine nucleosides (G)
abacavir
only NRTI shown to reduce perinatal HIV transmission
zidovudine
zidozudine is metabolized to …
glucoronide
abacavir is metabolized by …
alcohol dehydrogenase
which NRTI is acid labile and taken 1/2 hr before or 2 hour after meals?
didanosine
common toxicities of which group?: GI distress, lactic acidosis and hepatic steatosis due to mitochondrial toxicity; lipodystrophy
NRTIs
which NRTI can cause bone marrow suppression
zidovudine
which NRTI causes diarrhea, peripheral neuropathy, pancreatitis
didanosine
which NRTI causes peripheral neuropathy and pancreatitis
stavudine
which NRTI causes hypersensitivity reaction due to genetic predisposition
abacavir
which NRTI: avoid concurrent administration with drugs that are bone marrow suppressive
zidovudine
which NRTI: ganciclovir increases plasma conc 2X and methadone decreases plasma levels
didanosine
which NRTI: competition with zidovudine for activation enzymes
stavudine
which NRTI: trimethoprim-sulfamethoxazole increases plasma concentration
lamivudine
which NRTI: ethanol significantly increases plasma levels
abacavir
Tenofovir DF and emtricitadine
truvada
what is effective as antiretroviral chemoprophylaxis before exposure
truvada
mech of action of which group: bind directly to a hydrophobic pocket of the RT protein; induce conformational change in active site and block enzyme activity; do not require intracellular phosphorylation for activity
NNRTIs
NNRTI: CYP3A4 inhibitor
delavirdine
NNRTI: CYP3A4 inducers
efavirenz and nevirapine
which NNRTI: fever, fatigue, headache, somnolence, nausea, hepatotoxicity (elevated liver ezymes); may be severe and life-threatening
nevirapine
which NNRTI: neuropsychiatric (headache, dizzines, abnormal dreams), teratogenic in nonhuman primates (FDA Pregnancy Category D)
efavirenz
inhibits HIV-1 integrase which is needed for insertion of viral DNA into host genome; oral; glucuronidation in liver
raltegravir
not inducer, inhibitor or substrate of CYP3A4; metabolized by UDP glucouronosyltransferase (UGT)
raltegravir
what induces UGT
rifampin
what inhibits UGT
PI atazanavir
treatment of HIV as part of combination therapy and most effective ART available; effective in both acutely and chronic HIV-1 infected cells; effective in monocytes and macrophages; prevent cleavage of polyprotein and block viral maturation
protease inhibitors
which group: metabolized by cytochrome P-450 system; potent inhibitors of CYP3A4
protease inhibitors
which PI is used to increase plasma conc of other PIs
ritonavir
which drug lowers indinavir AUC and potentially other PIs
carbamazepine
which drug upregulates PIs AUC
ketoconazole
which drug’s AUC is augmented by PIs
sildenafil
which PIs reduce methadone AUC
ritonavir and lopinavir
adverse effects of which drugs: hyperlipidemia, insulin resistance and diabetes, lipodystrophy (buffalo hump and crix-belly), gynecomastia; increased bleeding risk in hemophiliacs; increased liver function tests
PIs
which PI: hepatotoxicity at high doses
ritonavir
which PI: alopecia, kidney stones, and renal insufficiency (patients should drink 2 liters/day)
indinavir
which PI: hyperbilirubinemia due to inhibition of UDP glucuronosyltransferase
atazanavir
which group: once phosphorylated by cellular kinases have greater affinity for viral reverse transcriptase than for cellular DNA polymerase
NRTIs
which group: do not undergo phosphorylation and have greater affinity for viral reverse transcriptase than for cellular DNA polymerase
NNRTIs
which group: greater affinity for HIV aspartyl protease than for human protease
PIs
block DNA synthesis by inactivation of viral DNA polymerase through direct binding and competition for dNTPs and by inducing viral DNA chain termination
nucleoside analogs
chain terminating effect following incorporation of a nucleotide analogue
acyclovir
absence of viral thymidine kinase gives … against nucleoside analogues
resistance
acyclic purine nucleoside analogues; indication: herpes simplex, following high IV dose: reversible renal dysfunction and neurologic toxicity
acyclovir and valacyclovir
acyclic purin nucleoside analogues: indications- CMV retinitis (activity 100x greater than acyclovir), oral CMV prophylaxis; adverse effect- myelosuppression
ganciclovir and valganciclovir
antiherpesvirus agents: oral alternative to acyclovir
penciclovir and famciclovir
antiherpesvirus agent: inhibits herpesvirus DNA polymerase»human DNA polymerase; potential human carcinogen; nephotoxicity, neutropenia, ocular hypotony
cidofovir
a non-nucleoside anti-HSV agent; inhibits cleavage of pyrophosphate from dNTP and blocks viral DNA synthesis; effective in CMV retinitis
foscarnet
myelosuppressant and has teratogenic potential
ganciclovir
nephrotoxic
cidofovir and foscarnet
anti-hep agent: nucleoside analog of guanosine; inhibits all 3 activities of HBV polymerase; equally active against lamivudine-resistan HBV; HBV exacerbation upon discontinuation of treatment
entecavir
anti-hep agent: nucleotide analog prodrug; active against all HCV genotypes; monotherapy not recommended; once daily oral; metabolized in liver and elimination is renal; extreme caution when used in combo with ribavirin (Pregnancy category X)
sofobuvir
anti HBV; nucleotide analog; inhibits HBV DNA polymerase; exacerbations of hepatitis after discontinuation; lactic acidosis
adefovir
nucleotide reverse transcriptase inhibitor
tenofovir
all nucleoside analogs- lactic acidosis and severe hepatomegaly with steatosis is a more common adverse effect in the treatment of …
HIV
inhibitors of transcription; potent cytokines that possess antiviral, immunomodulating and antiproliferative actions
interferons
3 main classes of human IFNs
alpha, beta and gamma
adverse effects: flu-like syndrome, nausea, vomiting, anorexia, CV abnormalities, myelosupression, neurotoxicity, hepatotoxicity, should not be administered during pregnancy
interferon alpha-2
nucleoside analog of guanosine; interference with synthesis of GTP and inhibits GTP 5’ capping of viral mRNA; dose dependent hemolytic anemia; bone marrow suppression
ribavirin
NS3/4A proteas inhibitors; block serine protease; potent inhibitors of CYP3A4/5
boceprevir and telaprevir
antiinfluenza; inhibitors of uncoating of virus; acts on maturation of influenza HA glycoprotein’ oral prophylaxis against influenza A (not B); good alternative to vaccine
amantadine, rimantadine
antiinfluenza; inhibitors of influenza neuraminidase; effective against influenza A and B
zanamivir, oseltamivir